Accordingly, we can propose that the reduction in serum MMP-9 levels by anti-TNF-α treatment may help inhibit the shedding of cell surface HSPGs, thereby preventing progression of atherosclerotic lesions in RA patients. This evidence concerns the gene MMP9 and rheumatoid arthritis.